HomeCompareHERB vs PFE

HERB vs PFE: Dividend Comparison 2026

HERB yields 12500.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HERB wins by $498747976996367872.00M in total portfolio value
10 years
HERB
HERB
● Live price
12500.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$498747976996367872.00M
Annual income
$491,020,681,003,619,800,000,000.00
Full HERB calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — HERB vs PFE

📍 HERB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHERBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HERB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HERB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HERB
Annual income on $10K today (after 15% tax)
$1,062,500.00/yr
After 10yr DRIP, annual income (after tax)
$417,367,578,853,076,800,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, HERB beats the other by $417,367,578,853,076,800,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HERB + PFE for your $10,000?

HERB: 50%PFE: 50%
100% PFE50/50100% HERB
Portfolio after 10yr
$249373988498183936.00M
Annual income
$245,510,340,501,809,900,000,000.00/yr
Blended yield
98.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HERB
No analyst data
Altman Z
0.8
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HERB buys
0
PFE buys
0
No recent congressional trades found for HERB or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHERBPFE
Forward yield12500.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$498747976996367872.00M$51.1K
Annual income after 10y$491,020,681,003,619,800,000,000.00$27,210.54
Total dividends collected$498235517183739840.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HERB vs PFE ($10,000, DRIP)

YearHERB PortfolioHERB Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,260,700$1,250,000.00$9,161$701.38+$1.25MHERB
2$148,626,986$147,278,037.38$8,610$859.79+$148.62MHERB
3$16,386,101,622$16,227,070,746.70$8,366$1,081.25+$16386.09MHERB
4$1,689,525,624,319$1,671,992,495,582.84$8,483$1,405.66+$1689525.62MHERB
5$162,924,168,596,046$161,116,376,178,025.50$9,084$1,907.24+$162924168.59MHERB
6$14,694,663,924,503,782$14,520,335,064,106,012.00$10,418$2,732.78+$14694663924.49MHERB
7$1,239,682,670,110,485,000$1,223,959,379,711,266,000.00$13,007$4,193.56+$1239682670110.47MHERB
8$97,827,968,310,781,350,000$96,501,507,853,763,130,000.00$18,010$7,005.87+$97827968310781.33MHERB
9$7,221,771,955,839,384,000,000$7,117,096,029,746,848,000,000.00$28,216$12,979.89+$7221771955839384.00MHERB
10$498,747,976,996,367,840,000,000$491,020,681,003,619,800,000,000.00$51,081$27,210.54+$498747976996367872.00MHERB

HERB vs PFE: Complete Analysis 2026

HERBStock

YaSheng Group, through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products primarily in the People's Republic of China. It cultivates, processes, markets, and distributes various food and agro-byproducts. The company's products include cotton, corns, barley, wheat, flax, and alfalfa; vegetables comprising onions, potatoes, beet, and peas; fruits, including apples, pears, and apricots; specialty crops consisting of hops, wolfberries, cumin, hemp, and liquorices; seeds, such as black melon, sunflower, corn, hemp, and flax seeds; and eggs. It also provides construction materials, such as cement; and designs, develops, and markets new technologies related to agriculture and genetic biology. The company sells its products to food processors, supermarkets, and wholesale stores through distributors, as well as to direct customers. YaSheng Group exports its products. The company was founded in 1998 and is based in Lanzhou, the People's Republic of China. As of December 31, 2015, YaSheng Group is a subsidiary of Gansu Yasheng Salt Chemical Industrial Group, Ltd.

Full HERB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HERB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HERB vs SCHDHERB vs JEPIHERB vs OHERB vs KOHERB vs MAINHERB vs JNJHERB vs MRKHERB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.